Inhaled insulin for the treatment of diabetes mellitus

McAuley L
Record ID 32001000956
English, French
Authors' objectives:

To summarise the available evidence on the use of inhaled insulin for the treatment of diabetes mellitus.

Authors' recommendations: - Insulin delivery via inhalation, as an alternative to administration by injection, is under development. - The available evidence comparing subcutaneous (sc) insulin with inhaled insulin for persons with type 1 and 2 diabetes, shows similar glycosylated hemoglobin (HgA1c) levels after three months of treatment. - Clinical trials suggest that insulin delivered by inhalation has a quicker onset of action relative to regular insulin. This means insulin can be taken just prior to a meal rather than the 30 minutes prior to eating required with sc injections of regular insulin. - No changes in pulmonary function were noted in the studies, however data is limited to use for three months. Pulmonary thrombosis has subsequently been reported in one patient out of 1000, using Exubera and the Inhale Therapeutic Systems device.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Diabetes Mellitus
  • Insulin
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.